All Phenotypes Pdzrn3<tm1.1Ysa> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/? Pdzrn3^tm1.1Ysa/Pdzrn3^tm1.1Ysa Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NCrlj * CBA * CBA/JNCrlj	MGI:5749858
cn2	Pdzrn3^tm1.1Ysa/Pdzrn3^tm1.1Ysa Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/?	involves: 129S/SvEv * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj	MGI:5749852
cn3	Pdzrn3^tm1.1Ysa/Pdzrn3^tm1.1Ysa Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?	involves: C57BL/6 * C57BL/6NCrlj * CBA * CBA/JNCrlj	MGI:5749855

Allelic Composition	Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/? Pdzrn3^tm1.1Ysa/Pdzrn3^tm1.1Ysa Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NCrlj * CBA * CBA/JNCrlj

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo} mutation (10 available); any Gt(ROSA)26Sor mutation (993 available)
Pdzrn3^tm1.1Ysa mutation (1 available); any Pdzrn3 mutation (51 available)
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

vision/eye

vision/eye phenotype ( J:222522 )

N	• embryos exposed to tamoxifen

abnormal retina vasculature morphology ( J:222522 )

• delayed vascularization of the superficial retinal vascular plexus at 5-12 days of age

• vessels are unstable

abnormal retina blood vessel morphology ( J:222522 )

• endothelial cell proliferation is increased

abnormal retina blood vessel pattern ( J:222522 )

• reduced vascular density and decreased number of branch points in the superficial retinal vascular plexus

• capillary network massively reduced in the deep capillary plexus

• capillary orientation in the superficial plexus relative to the deep plexus is disrupted

cardiovascular system

abnormal retina vasculature morphology ( J:222522 )

• delayed vascularization of the superficial retinal vascular plexus at 5-12 days of age

• vessels are unstable

abnormal retina blood vessel morphology ( J:222522 )

• endothelial cell proliferation is increased

abnormal retina blood vessel pattern ( J:222522 )

• reduced vascular density and decreased number of branch points in the superficial retinal vascular plexus

• capillary network massively reduced in the deep capillary plexus

• capillary orientation in the superficial plexus relative to the deep plexus is disrupted

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

embryonic lethality during organogenesis ( J:222522 )

• death between E11.5 and E12.5 of embryos exposed to tamoxifen between E7.5 and E9.5

• tamoxifen exposure between E10.5 and E12.5 does not induce lethality

embryo

embryo phenotype ( J:222522 )

N	• embryos exposed to tamoxifen between E7.5 and E9.5

embryonic growth retardation ( J:222522 )

• retarded growth at E9.5

abnormal extraembryonic tissue morphology ( J:222522 )

abnormal vitelline vasculature morphology ( J:222522 )

• yolk sac vascularization is altered between E9.5 and E10.5

abnormal vitelline artery morphology ( J:222522 )

• increased diameter of the vitellin artery

disorganized yolk sac vascular plexus ( J:222522 )

• disorganized vascular network by E11.5

abnormal placenta morphology ( J:222522 )

abnormal placental labyrinth vasculature morphology ( J:222522 )

• fetal capillaries do not invade the labyrinth

decreased placental labyrinth size ( J:222522 )

• reduced labyrinth layer of the placenta

cardiovascular system

abnormal brain vasculature morphology ( J:222522 )

• reduced brain vasculature at E11.5

abnormal placental labyrinth vasculature morphology ( J:222522 )

• fetal capillaries do not invade the labyrinth

abnormal vitelline vasculature morphology ( J:222522 )

• yolk sac vascularization is altered between E9.5 and E10.5

abnormal vitelline artery morphology ( J:222522 )

• increased diameter of the vitellin artery

disorganized yolk sac vascular plexus ( J:222522 )

• disorganized vascular network by E11.5

nervous system

nervous system phenotype ( J:222522 )

N	• embryos exposed to tamoxifen between E7.5 and E9.5

abnormal brain vasculature morphology ( J:222522 )

• reduced brain vasculature at E11.5

growth/size/body

embryonic growth retardation ( J:222522 )

• retarded growth at E9.5

Allelic Composition	Pdzrn3^tm1.1Ysa/Pdzrn3^tm1.1Ysa Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?
Genetic Background	involves: C57BL/6 * C57BL/6NCrlj * CBA * CBA/JNCrlj

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pdzrn3^tm1.1Ysa mutation (1 available); any Pdzrn3 mutation (51 available)
Tg(Pdgfb-icre/ERT2,-EGFP)1Frut mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

embryo

embryo phenotype ( J:222522 )

N	• embryos exposed to tamoxifen between E7.5 and E9.5

embryonic growth retardation ( J:222522 )

• retarded growth in 25% of embryos at E11.5

abnormal extraembryonic tissue morphology ( J:222522 )

abnormal placental labyrinth vasculature morphology ( J:222522 )

• decreased embryonic vessels in the labyrinth at E10.5

abnormal vitelline vasculature morphology ( J:222522 )

• yolk sac vascularization is altered

cardiovascular system

abnormal placental labyrinth vasculature morphology ( J:222522 )

• decreased embryonic vessels in the labyrinth at E10.5

abnormal vitelline vasculature morphology ( J:222522 )

• yolk sac vascularization is altered

growth/size/body

embryonic growth retardation ( J:222522 )

• retarded growth in 25% of embryos at E11.5

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/12/2024 MGI 6.24